Biomarkers for peripheral artery disease

Abstract

This invention provides biomarkers whose concentrations in blood plasma are associated with the presence or absence of PAD in the patient from whom the plasma sample is taken. The invention also provides biomarkers for distinguishing between PAD patients who are long claudicators and PAD patients who are not. In addition, the invention provides methods for identifying additional biomarkers, methods for detecting the biomarkers in patients, and methods for identifying agents, including pharmaceutical agents, which interact with the biomarkers and are useful for preventing or treating PAD in patients.

1 .- 70 . (canceled) 
     
     
         71 . A software product comprising:
 (a) code that accesses data attributed to a sample, the data comprising measurement of α1β glycoprotein in the sample, and   (b) code that executes a classification algorithm that classifies the PAD status of the sample as a function of the measurement.   
     
     
         72 . (canceled) 
     
     
         73 . The software product of  claim 72 , wherein the classification algorithm further classifies the PAD status of the sample as a function of the measurement of a biomarker selected from the group consisting of albumin, fetuin, triple charge dimer of albumin, transthyretin, and dimer of .alpha.1-antitrypsin. 
     
     
         74 . The software product of  claim 71 , wherein the classification algorithm classifies the PAD status of the sample as a function of the measurement of a biomarker selected from the group consisting of the biomarkers of Table 2. 
     
     
         75 . The software product of  claim 74 , wherein the classification algorithm classifies the PAD status of the sample as a function of the measurement of a biomarker selected from the group consisting of kappa chain of IgG, transthyretin and M23651.9. 
     
     
         76 . The software product of  claim 71 , wherein the classification algorithm classifies the PAD status of the sample as a function of the measurement of a biomarker selected from the group consisting of the biomarkers of Table 3. 
     
     
         77 . The software product of  claim 76 , wherein the classification algorithm classifies the PAD status of the sample as a function of the measurement of a biomarker selected from the group consisting of M75053.2, M18183.9 and M11950.4. 
     
     
         78 . The software product of  claim 71 , wherein the classification algorithm classifies the PAD status of the sample as a function of the measurement of a biomarker selected from the group consisting of the biomarkers of Table 18. 
     
     
         79 . A purified biomolecule selected from the biomarkers of Tables 1A, 1B, 2, 3, 4, 5, 6 and 18. 
     
     
         80 - 83 . (canceled)